

1652

A circular ink stamp from the OIPE JC139 Patent & Trademark Office. The text "OIPE JC139" is curved along the top inner edge, and "PATENT & TRADEMARK OFFICE" is curved along the bottom inner edge. In the center, the date "SEP 22 2003" is stamped horizontally.

[illegible]

Group Art Unit: 1652

Attorney
Docket: 01/22781

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

This Information Disclosure Statement is being submitted after the mailing of a substantive Office Action and a fee of \$180.00 is due. Please charge Deposit Account No. 50-1407 the required sum of \$180.00.

Respectfully submitted,

Sol Sheinbein

Registration No. 25,457

Date: August 14, 2003

A circular stamp from the Office of Intellectual Property and Trademark (OIPE). The text "OIPE" is at the top, "JC139" is at the top right, "SEP 22 2003" is in the center, and "PATENT & TRADEMARK OFFICE" is at the bottom. The stamp is partially overlapping the text "are required to respond to a co" and "IPRO".

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/988,113
Filing Date	March 1, 1999
First Named Inventor	Pecker et al
Group Art Unit	1652
Examiner Name	Hutson, Richard G.

Attorney Docket Number	01/22781
------------------------	----------

Sheet	1	of	3	Attorney Docket Number	01/22781
-------	---	----	---	------------------------	----------

--	--


--	--	--	--

Date of Publication of	Pages, columns, lines,
------------------------	------------------------

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/988,113	
			Filing Date	March 1, 1999	
			First Named Inventor	Pecker et al	
			Group Art Unit	1652	
			Examiner Name	Hutson, Richard G.	
Sheet	2	of	3	Attorney Docket Number	01/22781
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		Ernst et al, "Enzymatic Degradation of Glycosaminoglycans", <i>Critical Rev. in Biochemistry and Mol. Biology</i> , 30(5):387-444, 1995			
		Linhardt et al, "Polysaccharide Lyases", <i>Applied Biochemistry and Biotechnology</i> , 12:135-176, 1986			
		Kosir et al, "Human Prostrate Carcinoma Cells Produce Extracellular Heparanase", <i>J. Surgical Res.</i> , 67:98-105, 1997			
		Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degrative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem.</i> , 327:917-923, 1997			
		DeVouge et al, "Immunoselection of GRP94/Endoplasmin from a KNRK Cell-Specific λ gt11 Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", <i>Int. J. Cancer</i> , 56:286-294, 1994			
		Marchetti et al, "Neutrotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", <i>Cancer Research</i> , 56:2856-2863, 1996			
		Marchetti et al, "Neutrotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", <i>Advances in Enzyme Regulation</i> , 37:111-134, 1997			
		Jin et al, Immunochemical Localization of Heparanase in Mouse and Human Melanomas", <i>Int. J. Cancer</i> , 45:1088-1095, 1990			
		Fairbanks et al, "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", <i>J. Biol. Chem.</i> , 274(42):29587-29590, 1999			
		Toyoshima et al, "Human Heparanase", <i>J. Biol. Chem.</i> , 274(34):24153-24160, 1999			
		Hoogewerf et al, "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparain/Heparan Sulfate-degrading Enzymes", <i>J. Biol. Chem.</i> , 270(7):3268-3277, 1995			
		Freeman et al, "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", <i>Biochem. J.</i> , 342:361-368, 1999			
		Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", <i>Nature Medicine</i> , 5(7):793802, 1999			
		Hulett et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", <i>Nature Medicine</i> , 5(7):803-809, 1999			
		Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", Chap. 14 from " <i>The Protein Folding Problem and Tertiary Structure Prediction</i> ", Merz and LeGrand, Eds., Birkäuser, Boston, 1994			
		Oldberg et al, Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", <i>Biochemistry</i> , 19:5755-5762, 1980			
		Kussie et al, "Cloning and Functional Expression of a Human Heparanase Gene", <i>Biochem. And Biophysical Res. Comm.</i> , 261:183-187, 1999			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/988,113
				Filing Date	March 1, 1999
				First Named Inventor	Pecker et al
				Group Art Unit	1652
				Examiner Name	Hutson, Richard G.
Sheet	3	of	3	Attorney Docket Number	01/22781
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		Walch et al, Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor with Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", <i>Int. J. Cancer</i> , 82:112-120, 1999			
		Okamoto et al, "Highly Specific and Sensitive Detection of Malignancy in Urine Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", <i>Int. J. Cancer</i> , 79(6):560-564, 1998 (abstract only)			
		Zhou et al, "A 182 bp Fragment of the Mouse pro α 1(11) Collagen Gene is Sufficient to Direct Chondrocyte Expression in Transgenic Mice", <i>J. Cell Science</i> , 108:3677-3684, 1995			
		Hormuzdi et al, "A Gene-Targeting Approach Identifies a Function for the First Intron in Expression of the Alpha 1(I) Collagen Gene", <i>Mol. Cell Biol.</i> , 18(6):3368-3375, 1998 (abstract Only)			
		Kang et al, "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine Beta-Casein Gene", <i>Mol Cells</i> , 8(3):259-265, 1998 (abstract only)			
		Chow et al, "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airways", <i>Proc. Nat. Acad. Sci. USA</i> , 94:14695-14700, 1997			
		Gottschalk et al, "Somatic Gene Therapy. Present Situation and Future Perspective", <i>Arzneimittelforschung</i> , 48(11):1111-1120, 1998 (Abstract only)			
		Ye et al, "Targeted Gene Correction: A New Strategy for Molecular Medicine", <i>Molecular Medicine Today</i> , Oct. 1998, pp 431-437			
		Lai et al, "Homologous Recombination Based Gene Therapy", <i>Exp Nephrol</i> , 7(1):11-14, 1999 (abstract only)			
		Yazaki et al, "The structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissue", <i>Biochemica et Biophysica Acta</i> , 1172:37-42, 1993			
		Le Fur et al, "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", <i>Proc. Natl. Acad. Sci. USA</i> , 94:5332-5337, 1997			
		Guriec et al, "CD44 Isoforms with Exon v6 and Metastasis of Primary N0M0 Breast Carcinomas", <i>Breast Cancer Res Treat</i> , 44(3):261-268, 1997			
		Gewirtz et al, "Nucleic Acid Therapeutics: State of the Art and Future Prospects", <i>Blood</i> , 92(3):712-736, 1998			
		Hida et al, "Antisense E1AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", <i>Am J Pathol</i> , 50(6):2125-2132, 1997 (abstract only)			
		Shastri, BS, "Gene Disruption in Mice: Models of Development and Disease", <i>Molecular and Cellular Biochemistry</i> , 181:163-179, 1998			
		Carpentier et al, "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mice", <i>Clinical Cancer Research</i> , 4:2819-2824, 1998			
		Lai, et al, "DNA Vaccines", <i>Critical Reviews in Immunology</i> , 18:449-484, 1998			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.